Diabetes Market 2025 Share, COVID Impact, Trends Analysis Report 2035

Diabetes Market

SHARE ON:

Diabetes Market Size, Share & Trends Analysis Report by Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Class (Alpha-Glucosidase Inhibitors, Amylin Analogs, Antidiabetic Combinations, Dipeptidyl Peptidase 4 Inhibitors, Incretin Mimetics, Insulin, Meglitinides, Non-Sulfonylureas, Sglt-2 Inhibitors, Sulfonylureas, and Thiazolidinedione), and by Devices (Blood Glucose Meters, Blood Glucose Strips, Insulin Injection Pens, Insulin Syringes, Continuous Glucose Monitoring Systems, Insulin Pumps, and Lancets), Forecast Period (2025-2035)

Published: Feb 2026 | Report Code: OMR2028932 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Diabetes market was valued at $88.3 billion in 2024 and is projected to reach $354.9 billion by 2035, growing at a CAGR of 13.6% during the forecast period (2025–2035). The rising prevalence of diabetes, the advancement of treatment methods, and increased healthcare infrastructure investments are all driving market expansion. The increasing acceptance of digital health technologies, the integration of artificial intelligence (AI) in diabetes care, and the growing demand for innovative insulin delivery systems are all essential market growth factors. The widespread use of artificial pancreas systems and continuous glucose monitoring (CGM) sensors has significantly enhanced diabetes treatment, with improved patient outcomes and quality of life. In addition, the emergence of personalized therapy strategies, AI-based diagnostic technologies, and intelligent insulin pens is likely to drive the market growth. According to the International Diabetes Federation (IDF), by 2045, DF estimates indicate that 1 in 8 adults, i.e., 783 million, will have diabetes, a rise of 46.0% that calls for increased investment in advanced therapeutic technology. Increased applications of machine learning (ML) for predictive analytics, coupled with breakthroughs in biotechnological research, are fueling novel drug products and non-invasive monitoring technology. Further, government programs encouraging diabetes awareness, early detection, and better access to healthcare services are anticipated to continue fueling market growth.

diabetes market dynamics

Market Dynamics

Rising Awareness and Improved Diagnosis Driving Market Expansion

This growing incidence of type 2 diabetes is leading to a global demand for anti-diabetic medication, insulin treatments, blood glucose monitors, and associated care products. According to the International Diabetes Federation (IDF), in April 2025, diabetes facts show an escalating global burden impacting people, families, and nations. There are now 11.1% of adults aged 20-79, or 1 in 9, with diabetes, of whom over 40% are undiagnosed. Projections are that by 2050, 1 in 8 adults, or 853 million, will have diabetes, a 46% increase. Over 90% of them will have type 2 diabetes, driven by socio-economic, demographic, environmental, and genetic factors. Urbanization, population aging, physical inactivity, and rising overweight and obesity are the major drivers. Prevention of type 2 diabetes and early treatment and diagnosis for all forms will go a long way to prevent complications.

rising awareness and improved diagnosis driving market expansion

Rising Awareness and Improved Diagnosis Driving Market Expansion

The market is expanding as awareness and diagnosis rise, increasing the need for monitoring and therapeutic solutions. For instance, in April 2025, the Indian Diabetes Federation (IDF) established a working group to create diagnostic criteria and therapeutic guidelines for type 5 diabetes, an illness associated with malnutrition. The group established a global research registry and created education modules for healthcare providers. Type 5 diabetes affects 20-25 million people worldwide, primarily in Asia and Africa. Although it has been observed for over 70 years, it has been mostly minimised in global health proceedings. The community strives to raise awareness about diabetes and the role of lean and malnourished people in countries with low or middle incomes.

Market Segmentation

Based on the type, the market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes.
Based on the drug class, the market is segmented into alpha-glucosidase inhibitors, amylin analogs, antidiabetic combinations, dipeptidyl peptidase 4 inhibitors, incretin mimetics, insulin, meglitinides, non-sulfonylureas, SGLT-2 inhibitors, sulfonylureas, and thiazolidinediones.
Based on the devices, the market is segmented into blood glucose meters, blood glucose strips, insulin injection pens, insulin syringes, continuous glucose monitoring systems, insulin pumps, and lancets.

Continuous Glucose Monitoring Systems: A Key Segment in Market Growth

Continuous Glucose Monitoring Systems (CGMs) are ambulatory medical devices that track blood glucose levels continuously and relay real-time information for optimal decision-making regarding diet, exercise, and medication. Market growth is the consequence of technology developments that improve CGM accuracy, reduce lag time, and increase patient comfort. For instance, in April 2025, Dexcom obtained FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring system for patients aged 18 years and older. The device is extended wear for 15.5 days and has a mean absolute relative difference of 8.0%. The device offers wearability, accuracy, and integration advantages that impact clinical care, payer coverage, and digital health ecosystems.

Regional Outlook

The global diabetes market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Increased Incidence of Obesity In North America

Obesity is a long-term medical condition of abnormal or excessive fat accumulation in the body that can lead to health conditions such as diabetes, heart disease, and certain cancers. Furthermore, obesity, a key driver of insulin resistance and type 2 diabetes, is propelling both market and disease burden growth globally. For instance, in June 2024, the American Diabetes Association (ADA) launched the Obesity Association, a department that aims to reduce obesity levels and improve health outcomes. The ADA has long supported and promoted diabetes therapies in funding and advocating for obesity treatments. Despite advances in research and treatment, obesity remains a major health issue, affecting more than 40% of adults in the US.

Asia-Pacific Maintains Strong Market Position

Asia-Pacific holds a significant share, as a result of the market expansion is largely due to the mounting incidence of type 2 diabetes, especially in emerging nations like India and China. For instance, in July 2025, Eli Lilly launched Mounjaro KwikPen, a weekly-dosed single-use prefilled pen for its best-selling diabetes drug, Mounjaro, in India. The easy treatment option is intended to help adults with type 2 diabetes manage their blood glucose levels and weight.

Market Players Outlook

The major companies operating in the global diabetes market include Abbott Laboratories, Dexcom, Inc., Eli Lilly and Co., Medtronic MiniMed, Inc., and Novo Nordisk A/S, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In April 2025, Cardinal Health acquired Advanced Diabetes Supply Group (ADSG), offering innovative diabetes therapies such as continuous glucose monitors, to support individual patients in their homes, aligning with the company's strategy to expand its services.
In February 2025, Biocon Ltd., a global biopharmaceutical company driven by innovation, launched its GLP-1 peptide Liraglutide in the UK for the treatment of diabetes and obesity. The medicine-device combination will be available in the UK under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda).

The Report Covers

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global diabetes market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.

Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Diabetes Market Sales Analysis – Type | Drug Class | Devices ($ Million)
Diabetes Market Sales Performance of Top Countries
- Research Methodology
Primary Research Approach
Secondary Research Approach
- Market Snapshot

Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
  - Key Diabetes Market Trends
  - Market Recommendations

Market Determinants
- Market Drivers
  - Drivers For Global Diabetes Market: Impact Analysis
- Market Pain Points and Challenges
  - Restraints For Global Diabetes Market: Impact Analysis
- Market Opportunities
  - Opportunities For Global Diabetes Market: Impact Analysis

Competitive Landscape
- Competitive Dashboard – Diabetes Market Revenue and Share by Manufacturers

Diabetes Product Comparison Analysis
Top Market Player Ranking Matrix
- Key Company Analysis
  - Abbott Laboratories
    - Overview
    - TypePortfolio
    - Financial Analysis (Subject to Data Availability)
    - SWOT Analysis
    - Business Strategy
  - Dexcom, Inc.
    - Overview
    - TypePortfolio
    - Financial Analysis (Subject to Data Availability)
    - SWOT Analysis
    - Business Strategy
  - Eli Lilly and Co.
    - Overview
    - TypePortfolio
    - Financial Analysis (Subject to Data Availability)
    - SWOT Analysis
    - Business Strategy
  - Medtronic MiniMed, Inc.
    - Overview
    - TypePortfolio
    - Financial Analysis (Subject to Data Availability)
    - SWOT Analysis
    - Business Strategy
  - Novo Nordisk A/S
    - Overview
    - TypePortfolio
    - Financial Analysis (Subject to Data Availability)
    - SWOT Analysis
    - Business Strategy

Top Winning Strategies by Market Players
- Merger and Acquisition
- Type Launch
- Partnership And Collaboration

Global Diabetes Market Sales Analysis by Type ($ Million)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational

Global Diabetes Market Sales Analysis by Drug Class ($ Million)
- Alpha-Glucosidase Inhibitors
- Amylin Analogs
- Antidiabetic Combinations
- Dipeptidyl Peptidase 4 Inhibitors
- Incretin Mimetics
- Insulin
- Meglitinides
- Non-Sulfonylureas
- Sglt-2 Inhibitors
- Sulfonylureas
- Thiazolidinedione

Global Diabetes Market Sales Analysis by Devices ($ Million)
- Blood Glucose Meters
- Blood Glucose Strips
- Insulin Injection Pens
- Insulin Syringes
- Continuous Glucose Monitoring Systems
- Insulin Pumps
- Lancets

Regional Analysis
- North American Diabetes Market Sales Analysis – Type | Drug Class | Devices ($ Million)

Macroeconomic Factors for North America
- United States
- Canada

European Diabetes Market Sales Analysis – Type | Drug Class | Devices ($ Million)

Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe

Asia-Pacific Diabetes Market Sales Analysis – Type | Drug Class | Devices ($ Million)

Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And others)
- Rest of Asia-Pacific

Rest of the World Diabetes Market Sales Analysis – Type | Drug Class | Devices ($ Million)

Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa

Company Profiles
- Abbott Laboratories
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- AstraZeneca
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Biocon Ltd.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Boehringer Ingelheim International GmbH
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Dexcom, Inc.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Eli Lilly and Co.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Hoffmann-La Roche Ltd.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- GlaxoSmithKline plc
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Glenmark Pharmaceuticals Ltd.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Janssen Inc.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Lupin Ltd.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Medtronic MiniMed, Inc.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Novartis Pharmaceuticals Corp.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Novo Nordisk A/S
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Pfizer Inc.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Sanofi-Aventis Philippines Inc.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies
- Takeda Pharmaceutical Co. Ltd.
  - Quick Facts
  - Company Overview
  - Product Portfolio
  - Business Strategies

1. Global Diabetes Market Research And Analysis By Type, 2024-2035 ($ Million)

2. Global Type 1 Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

3. Global Type 2 Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

4. Global Gestational Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

5. Global Diabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)

6. Global Alpha-Glucosidase Inhibitors For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

7. Global Amylin Analogs For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

8. Global Antidiabetic Combinations For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

9. Global Dipeptidyl Peptidase 4 Inhibitors For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

10. Global Incretin Mimetics For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

11. Global Insulin For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

12. Global Meglitinides For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

13. Global Non-Sulfonylureas For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

14. Global SGLT-2 Inhibitors For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

15. Global Sulfonylureas For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

16. Global Thiazolidinedione For Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

17. Global Diabetes Market Research And Analysis By Devices, 2024-2035 ($ Million)

18. Global Blood Glucose Meters Market Research And Analysis By Region, 2024-2035 ($ Million)

19. Global Blood Glucose Strips Market Research And Analysis By Region, 2024-2035 ($ Million)

20. Global Insulin Injection Pens Market Research And Analysis By Region, 2024-2035 ($ Million)

21. Global Insulin Syringes Market Research And Analysis By Region, 2024-2035 ($ Million)

22. Global Continuous Glucose Monitoring Systems Market Research And Analysis By Region, 2024-2035 ($ Million)

23. Global Insulin Pumps Market Research And Analysis By Region, 2024-2035 ($ Million)

24. Global Lancets Market Research And Analysis By Region, 2024-2035 ($ Million)

25. Global Diabetes Market Research And Analysis By Region, 2024-2035 ($ Million)

26. North American Diabetes Market Research And Analysis By Country, 2024-2035 ($ Million)

27. North American Diabetes Market Research And Analysis By Type, 2024-2035 ($ Million)

28. North American Diabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)

29. North American Diabetes Market Research And Analysis By Devices, 2024-2035 ($ Million)

30. European Diabetes Market Research And Analysis By Country, 2024-2035 ($ Million)

31. European Diabetes Market Research And Analysis By Type, 2024-2035 ($ Million)

32. European Diabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)

33. European Diabetes Market Research And Analysis By Devices, 2024-2035 ($ Million)

34. Asia-Pacific Diabetes Market Research And Analysis By Country, 2024-2035 ($ Million)

35. Asia-Pacific Diabetes Market Research And Analysis By Type, 2024-2035 ($ Million)

36. Asia-Pacific Diabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)

37. Asia-Pacific Diabetes Market Research And Analysis By Devices, 2024-2035 ($ Million)

38. Rest Of The World Diabetes Market Research And Analysis By Country, 2024-2035 ($ Million)

39. Rest Of The World Diabetes Market Research And Analysis By Type, 2024-2035 ($ Million)

40. Rest Of The World Diabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)

41. Rest Of The World Diabetes Market Research And Analysis By Devices, 2024-2035 ($ Million)